Disorders of glucose metabolism in Prader–Willi syndrome: Results of a multicenter Italian cohort study

D. Fintini, G. Grugni, S. Bocchini, C. Brufani, S. Di Candia, A. Corrias, M. Delvecchio, A. Salvatoni, L. Ragusa, N. Greggio, A. Franzese, E. Scarano, G. Trifirò, L. Mazzanti, G. Chiumello, M. Cappa, A. Crinò

Research output: Contribution to journalArticle

Abstract

Background and aims Prader–Willi syndrome (PWS) is characterized by a high incidence of altered glucose metabolism (AGM). However, epidemiological data on impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) are still discordant. Methods and results We performed a multicenter study based on 274 PWS patients [144 females, aged 20.3 ± 10.4 yrs (range: 8.1–50.1 years)] evaluating the prevalence for AGM in the entire group, and according to age (children 18 yrs), Body Mass Index (BMI = kg/m2), gender, genotypes (deletion or uniparental disomy for chromosome 15), and GH therapy (GHT) (untreated, previously or currently treated). Altogether, AGM was detected in 67 (24.4%) of patients (0.7% IFG, 10.2% IGT, 13.5% T2DM). The prevalence of AGM was correlated to age (p = 0.001), BMI (p = 0.001) and HOMA-IR (p = 0.001). However, gender, genotype, and GHT did not influence AGM development in univariate analysis. These data were confirmed as positive predictors when inserted in a multivariate analysis model. Conclusion This study is the first report on the prevalence of AGM in a large population of PWS. Overall, PWS subjects show a high prevalence of AGM that appears more common in obese and adult subjects. Our data confirm the main role of obesity on the individual metabolic risk clustering in PWS, and thus reinforce the concept that improvement in weight control remains the most important goal of any PWS treatment program.
Original languageEnglish
Pages (from-to)842 - 847
Number of pages6
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume26
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Glucose Metabolism Disorders
Cohort Studies
Glucose
Glucose Intolerance
Type 2 Diabetes Mellitus
Fasting
Genotype
Chromosomes, Human, Pair 15
Multicenter Studies
Cluster Analysis
Body Mass Index
Therapeutics
Multivariate Analysis
Obesity

Keywords

  • Diabetes mellitus
  • GH therapy
  • Obesity
  • Prader–Willi syndrome

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Disorders of glucose metabolism in Prader–Willi syndrome: Results of a multicenter Italian cohort study. / Fintini, D.; Grugni, G.; Bocchini, S.; Brufani, C.; Di Candia, S.; Corrias, A.; Delvecchio, M.; Salvatoni, A.; Ragusa, L.; Greggio, N.; Franzese, A.; Scarano, E.; Trifirò, G.; Mazzanti, L.; Chiumello, G.; Cappa, M.; Crinò, A.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 26, No. 9, 01.09.2016, p. 842 - 847.

Research output: Contribution to journalArticle

Fintini, D, Grugni, G, Bocchini, S, Brufani, C, Di Candia, S, Corrias, A, Delvecchio, M, Salvatoni, A, Ragusa, L, Greggio, N, Franzese, A, Scarano, E, Trifirò, G, Mazzanti, L, Chiumello, G, Cappa, M & Crinò, A 2016, 'Disorders of glucose metabolism in Prader–Willi syndrome: Results of a multicenter Italian cohort study', Nutrition, Metabolism and Cardiovascular Diseases, vol. 26, no. 9, pp. 842 - 847. https://doi.org/10.1016/j.numecd.2016.05.010
Fintini, D. ; Grugni, G. ; Bocchini, S. ; Brufani, C. ; Di Candia, S. ; Corrias, A. ; Delvecchio, M. ; Salvatoni, A. ; Ragusa, L. ; Greggio, N. ; Franzese, A. ; Scarano, E. ; Trifirò, G. ; Mazzanti, L. ; Chiumello, G. ; Cappa, M. ; Crinò, A. / Disorders of glucose metabolism in Prader–Willi syndrome: Results of a multicenter Italian cohort study. In: Nutrition, Metabolism and Cardiovascular Diseases. 2016 ; Vol. 26, No. 9. pp. 842 - 847.
@article{a194072c30bd468f91d45be1d6de6f71,
title = "Disorders of glucose metabolism in Prader–Willi syndrome: Results of a multicenter Italian cohort study",
abstract = "Background and aims Prader–Willi syndrome (PWS) is characterized by a high incidence of altered glucose metabolism (AGM). However, epidemiological data on impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) are still discordant. Methods and results We performed a multicenter study based on 274 PWS patients [144 females, aged 20.3 ± 10.4 yrs (range: 8.1–50.1 years)] evaluating the prevalence for AGM in the entire group, and according to age (children 18 yrs), Body Mass Index (BMI = kg/m2), gender, genotypes (deletion or uniparental disomy for chromosome 15), and GH therapy (GHT) (untreated, previously or currently treated). Altogether, AGM was detected in 67 (24.4{\%}) of patients (0.7{\%} IFG, 10.2{\%} IGT, 13.5{\%} T2DM). The prevalence of AGM was correlated to age (p = 0.001), BMI (p = 0.001) and HOMA-IR (p = 0.001). However, gender, genotype, and GHT did not influence AGM development in univariate analysis. These data were confirmed as positive predictors when inserted in a multivariate analysis model. Conclusion This study is the first report on the prevalence of AGM in a large population of PWS. Overall, PWS subjects show a high prevalence of AGM that appears more common in obese and adult subjects. Our data confirm the main role of obesity on the individual metabolic risk clustering in PWS, and thus reinforce the concept that improvement in weight control remains the most important goal of any PWS treatment program.",
keywords = "Diabetes mellitus, GH therapy, Obesity, Prader–Willi syndrome",
author = "D. Fintini and G. Grugni and S. Bocchini and C. Brufani and {Di Candia}, S. and A. Corrias and M. Delvecchio and A. Salvatoni and L. Ragusa and N. Greggio and A. Franzese and E. Scarano and G. Trifir{\`o} and L. Mazzanti and G. Chiumello and M. Cappa and A. Crin{\`o}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.numecd.2016.05.010",
language = "English",
volume = "26",
pages = "842 -- 847",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier B.V.",
number = "9",

}

TY - JOUR

T1 - Disorders of glucose metabolism in Prader–Willi syndrome: Results of a multicenter Italian cohort study

AU - Fintini, D.

AU - Grugni, G.

AU - Bocchini, S.

AU - Brufani, C.

AU - Di Candia, S.

AU - Corrias, A.

AU - Delvecchio, M.

AU - Salvatoni, A.

AU - Ragusa, L.

AU - Greggio, N.

AU - Franzese, A.

AU - Scarano, E.

AU - Trifirò, G.

AU - Mazzanti, L.

AU - Chiumello, G.

AU - Cappa, M.

AU - Crinò, A.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background and aims Prader–Willi syndrome (PWS) is characterized by a high incidence of altered glucose metabolism (AGM). However, epidemiological data on impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) are still discordant. Methods and results We performed a multicenter study based on 274 PWS patients [144 females, aged 20.3 ± 10.4 yrs (range: 8.1–50.1 years)] evaluating the prevalence for AGM in the entire group, and according to age (children 18 yrs), Body Mass Index (BMI = kg/m2), gender, genotypes (deletion or uniparental disomy for chromosome 15), and GH therapy (GHT) (untreated, previously or currently treated). Altogether, AGM was detected in 67 (24.4%) of patients (0.7% IFG, 10.2% IGT, 13.5% T2DM). The prevalence of AGM was correlated to age (p = 0.001), BMI (p = 0.001) and HOMA-IR (p = 0.001). However, gender, genotype, and GHT did not influence AGM development in univariate analysis. These data were confirmed as positive predictors when inserted in a multivariate analysis model. Conclusion This study is the first report on the prevalence of AGM in a large population of PWS. Overall, PWS subjects show a high prevalence of AGM that appears more common in obese and adult subjects. Our data confirm the main role of obesity on the individual metabolic risk clustering in PWS, and thus reinforce the concept that improvement in weight control remains the most important goal of any PWS treatment program.

AB - Background and aims Prader–Willi syndrome (PWS) is characterized by a high incidence of altered glucose metabolism (AGM). However, epidemiological data on impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) are still discordant. Methods and results We performed a multicenter study based on 274 PWS patients [144 females, aged 20.3 ± 10.4 yrs (range: 8.1–50.1 years)] evaluating the prevalence for AGM in the entire group, and according to age (children 18 yrs), Body Mass Index (BMI = kg/m2), gender, genotypes (deletion or uniparental disomy for chromosome 15), and GH therapy (GHT) (untreated, previously or currently treated). Altogether, AGM was detected in 67 (24.4%) of patients (0.7% IFG, 10.2% IGT, 13.5% T2DM). The prevalence of AGM was correlated to age (p = 0.001), BMI (p = 0.001) and HOMA-IR (p = 0.001). However, gender, genotype, and GHT did not influence AGM development in univariate analysis. These data were confirmed as positive predictors when inserted in a multivariate analysis model. Conclusion This study is the first report on the prevalence of AGM in a large population of PWS. Overall, PWS subjects show a high prevalence of AGM that appears more common in obese and adult subjects. Our data confirm the main role of obesity on the individual metabolic risk clustering in PWS, and thus reinforce the concept that improvement in weight control remains the most important goal of any PWS treatment program.

KW - Diabetes mellitus

KW - GH therapy

KW - Obesity

KW - Prader–Willi syndrome

UR - http://www.scopus.com/inward/record.url?scp=84991011521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991011521&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2016.05.010

DO - 10.1016/j.numecd.2016.05.010

M3 - Article

VL - 26

SP - 842

EP - 847

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 9

ER -